The webinar will be a discussion of the 48 Week dystrophin and 6-minute walk test (6MWT) data from the Phase IIb extension study in Duchenne as well as next steps for the eteplirsen program. Chris Garabedian, President and CEO of Sarepta Therapeutics will be presenting the data and answering submitted questions.

If you have questions you would like to submit to Sarepta, please email us at info@ParentProjectMD.org with “Sarepta Webinar” as the subject line. We will pass along all questions to Sarepta representatives prior to the 10/23 webinar.Please submit your questions no later than Friday, October 19 at noon eastern.

We appreciate Sarepta’s ongoing efforts to keep open lines of communications. We are always grateful when industry takes the time to communicate with the Duchenne community directly.

To Participate:

1. Visit ReadyTalk.com and use participant code 9449985. (Be sure to test your computer beforehand)
2. Audio Dial-In Information:
   • U.S. & Canada: Dial 866.740.1260 and use the Access Code 9449985
   • Outside the U.S. and Canada: Lookup your number